NCM · Biotechnology

CLGN (CLGN) Stock

$0.27 -9.04% NCM: CLGN Healthcare

Valuation

MetricValue
Price$0.27
Market Cap$3.54M
P/E Ratio-0.48
P/B Ratio0.92
P/S Ratio2.32
EPS (TTM)$-0.94
52-Week High$3.23
52-Week Low$0.27
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-183.33%
ROA-100.00%
ROCE-183.33%
Gross Margin-600.00%
Operating Margin-550.00%
Net Margin-4.85%
Debt/Equity0.47
Current Ratio2.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$16.0M$0$11.0M$1.0M$2.0M
Operating Profit$0$-17.0M$-8.0M$-17.0M$-11.0M
Net Profit$0$-17.0M$-7.0M$-17.0M$-11.0M
EPS$0.03$-1.52$-0.62$-1.45$-0.94
Op Margin0.4%-5718.1%-68.5%-3349.7%-484.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$51.0M$38.0M$34.0M$19.0M$11.0M
Total Liabilities$6.0M$5.0M$6.0M$5.0M$5.0M
Cash$13.0M$30.0M$27.0M$12.0M$6.0M
Borrowings$4.0M$3.0M$3.0M$3.0M$3.0M

Latest News

CollPlant Biotechnologies Files Prospectus for Resale of 31 Million Shares MT Newswires · Jul 9, 2026 COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT PR Newswire · Jun 30, 2026 COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR Newswire · May 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$3.0M$-14.0M$-3.0M$-14.0M$-9.0M
Investing Cash Flow$-33.0M$28.0M$-2.0M$-1.0M$0
Financing Cash Flow$39.0M$2.0M$1.0M$0$0
Net Cash Flow$10.0M$16.0M$-3.0M$-15.0M$-6.0M
Free Cash Flow$1.0M$-15.0M$-4.0M$-15.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-176.79%
Quick Ratio2.31
Interest Coverage—
Return 1Y-79.83%
Return 3Y-94.79%
Return 5Y-98.11%

Ownership

Insiders Held20.50%
Institutions Held9.18%
Institutions Float Held11.54%
Institutional HolderSharesReport Date
Villere St. Denis J. & Co. LLC607,3002026-03-31
Pinnacle Associates, Ltd.550,2292026-03-31
Brown Advisory Inc.118,7312026-03-31
Armistice Capital, LLC64,0002026-03-31
Pathstone Holdings, LLC57,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CVKD $2.06 +0.98% -0.78 $6.38M 0.00%
ENLV $2.12 -5.36% 0.03 $35.68M 0.00%
KLTOKlotho Neurosciences, Inc. $0.38 -7.10% -1.13 $20.08M 0.00%
MTVA $1.42 -1.39% -0.16 $3.13M 0.00%
NRSNNeuroSense Therapeutics Ltd. $0.60 -0.35% -1.35 $21.21M 0.00%

About CLGN

CLGN is led by CEO Yehiel Tal, employs 57 people, headquartered in IL, publicly traded since 2018.

CLGN stock trades at $0.27 with a market capitalization of $3.54M. The stock is valued at a price-to-earnings (P/E) ratio of -0.48, price-to-book of 0.92, price-to-sales of 2.32. Over the past 52 weeks the stock has ranged between $0.27 and $3.23, and currently trades 91.6% below its 52-week high.

On profitability, CLGN generates a return on equity (ROE) of -183.33%, return on capital employed of -183.33%, an operating margin of -550.00%, a net profit margin of -4.85%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides